102 results
8-K
EX-99.1
MBOT
Microbot Medical Inc
29 Apr 24
Regulation FD Disclosure
8:30am
BRAINTREE, Mass., April 29, 2024 – Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic Surgical System
8-K
EX-99.1
MBOT
Microbot Medical Inc
30 Jan 24
Microbot Medical Announces Settlement and Release Agreement, Effectively Resolving all Associated Legal Matters
7:20am
., January 30, 2024 – Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic Surgical System, today announced
8-K
EX-99.1
MBOT
Microbot Medical Inc
18 Jan 24
Microbot Medical Expands US Clinical Infrastructure in Support of the Upcoming IDE Submission to Commence its First in Human Clinical Study
7:20am
clinical study
BRAINTREE, Mass., January 18, 2023 – Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic
8-K
EX-99.1
MBOT
Microbot Medical Inc
2 Jan 24
Entry into a Material Definitive Agreement
4:55pm
At-the-Market Under Nasdaq Rules
BRAINTREE, Mass., Dec. 29, 2023 — Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular
8-K
EX-99.1
MBOT
Microbot Medical Inc
14 Dec 23
Microbot Medical and Corewell Health Forge Collaboration to Establish the LIBERTY® Endovascular Robotic Surgical System for Telerobotic
8:15am
Endovascular treatments.
BRAINTREE, Mass., December 14, 2023 – Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular
8-K
EX-99.1
rc9fepkkbw2k1044km
7 Dec 23
The results of the study will support the Company’s IDE submission to the FDA to commence its human clinical study
8:00am
8-K
EX-99.1
gf3oq8w6w4xt ohm2hh
21 Nov 23
Departure of Directors or Certain Officers
8:30am
8-K
EX-99.1
iyciqbtqb41ei7b2
13 Nov 23
Microbot Medical Successfully Completed Integral Part of the Verification and Validation Process
8:30am
8-K
EX-99.1
yu7jpbf3rlkv
31 Oct 23
Regulation FD Disclosure
8:25am
8-K
EX-99.1
97jmj9znnpa4mxq
24 Oct 23
Microbot Medical Received Confirmation for the Commencement of Its CE Mark Approval Process During the First Half of 2024
8:30am
8-K
EX-99.1
to1khiy19p03j
19 Oct 23
Microbot Medical Announces Grant of Summary Judgment in its Favor and Dismissal of Counterclaim Against Company
8:20am
8-K
EX-99.1
whakzm6x
17 Oct 23
Microbot Medical Announces Successful Initial Outcomes from Its Pivotal Pre-Clinical Study with the LIBERTY® Robotic Surgical System
9:09am
424B5
downqiuh44th6
28 Jun 23
Prospectus supplement for primary offering
7:14am
8-K
7t760v coj
22 Jun 23
Received Grant of Protection for a Design Patent in Japan Covering its Innovative LIBERTY® Robotic Drive
8:30am
8-K
EX-99.1
iash3mu
22 Jun 23
Received Grant of Protection for a Design Patent in Japan Covering its Innovative LIBERTY® Robotic Drive
8:30am
424B5
qsik fx5w
5 Jun 23
Prospectus supplement for primary offering
5:21pm
8-K
EX-99.1
i7wzmcqg4tk ec
25 May 23
This Significant Achievement Represents Major Progression Toward Regulatory and Commercialization Paths
10:07am
424B5
33e3v
24 May 23
Prospectus supplement for primary offering
11:15am
424B5
nhkvfqj230
23 May 23
Prospectus supplement for primary offering
12:55pm
8-K
EX-99.1
hspned9ww xwh88lt
8 May 23
Microbot Medical Initiates Preparations for First-In-Human (FIH) Cases in Brazil for the LIBERTY® Robotic System
8:30am